{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:23:03Z","timestamp":1791318183498,"version":"4.3.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00198-017-3992-5","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T10:03:33Z","timestamp":1489572213000},"page":"1995-2002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Factors associated with acute-phase response of bisphosphonate-na\u00efve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate"],"prefix":"10.1007","volume":"28","author":[{"given":"A.W.","family":"Popp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Curkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Buffat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.F.","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7195-3779","authenticated-orcid":false,"given":"K.","family":"Lippuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"3992_CR1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committee of Scientific Advisors of the International Osteoporosis F (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int : J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Foundat USA 24:23\u201357","journal-title":"Osteoporos Int : J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Foundat USA"},{"key":"3992_CR2","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis F (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int : J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Foundat USA 25:2359\u20132381","journal-title":"Osteoporos Int : J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Foundat USA"},{"issue":"Suppl 1","key":"3992_CR3","first-page":"S23","volume":"8","author":"H Fleisch","year":"1987","unstructured":"Fleisch H (1987) Bisphosphonates\u2014history and experimental basis. Bone 8(Suppl 1):S23\u2013S28","journal-title":"Bone"},{"key":"3992_CR4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF02547227","volume":"11","author":"A Jung","year":"1973","unstructured":"Jung A, Bisaz S, Fleisch H (1973) The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11:269\u2013280","journal-title":"Calcif Tissue Res"},{"issue":"Suppl 2","key":"3992_CR5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jbmr.5650140212","volume":"14","author":"RG Russell","year":"1999","unstructured":"Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C, Fleisch HA (1999) The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res Off J Am Soc Bone Miner Res 14(Suppl 2):53\u201365","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3992_CR6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0022-2275(20)41388-4","volume":"33","author":"D Amin","year":"1992","unstructured":"Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657\u20131663","journal-title":"J Lipid Res"},{"key":"3992_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","volume":"144","author":"AJ Roelofs","year":"2009","unstructured":"Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K (2009) Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP. Br J Haematol 144:245\u2013250","journal-title":"Br J Haematol"},{"key":"3992_CR8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1359\/JBMR.0301230","volume":"19","author":"K Thompson","year":"2004","unstructured":"Thompson K, Rogers MJ (2004) Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res Off J Am Soc Bone Miner Res 19:278\u2013288","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3992_CR9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V (1987) The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326\u2013331","journal-title":"Calcif Tissue Int"},{"key":"3992_CR10","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C et al (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838\u20131846","journal-title":"Arthritis Rheum"},{"key":"3992_CR11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"3992_CR12","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380\u20134387","journal-title":"J Clin Endocrinol Metab"},{"key":"3992_CR13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40261-012-0041-1","volume":"33","author":"P Sieber","year":"2013","unstructured":"Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C (2013) Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clin Drug Investig 33:117\u2013122","journal-title":"Clin Drug Investig"},{"key":"3992_CR14","doi-asserted-by":"crossref","unstructured":"(1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646\u2013650","DOI":"10.1016\/0002-9343(93)90218-E"},{"key":"3992_CR15","unstructured":"(1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. World Health Organ Tech Rep Ser 843:1\u2013129"},{"key":"3992_CR16","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1359\/jbmr.1997.12.11.1761","volume":"12","author":"AC Looker","year":"1997","unstructured":"Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1997) Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res Off J Am Soc Bone Miner Res 12:1761\u20131768","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3992_CR17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"AC Looker","year":"1998","unstructured":"Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int :J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA 8:468\u2013489","journal-title":"Osteoporos Int :J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"3992_CR18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","volume":"16","author":"JT Schousboe","year":"2013","unstructured":"Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom : Off J Int Soc Clin Densitom 16:455\u2013466","journal-title":"J Clin Densitom : Off J Int Soc Clin Densitom"},{"key":"3992_CR19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jocd.2006.05.003","volume":"9","author":"D Hans","year":"2006","unstructured":"Hans D, Downs RW Jr, Duboeuf F, Greenspan S, Jankowski LG, Kiebzak GM, Petak SM (2006) Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J Clin Densitom : Off J Int Soc Clin Densitom 9:15\u201321","journal-title":"J Clin Densitom : Off J Int Soc Clin Densitom"},{"key":"3992_CR20","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00198-008-0808-7","volume":"20","author":"AW Popp","year":"2009","unstructured":"Popp AW, Senn C, Franta O, Krieg MA, Perrelet R, Lippuner K (2009) Tibial or hip BMD predict clinical fracture risk equally well: results from a prospective study in 700 elderly Swiss women. Osteoporos Int :J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA 20:1393\u20131399","journal-title":"Osteoporos Int :J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"3992_CR21","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357 nihpa40967"},{"key":"3992_CR22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1359\/jbmr.090819","volume":"25","author":"F Bertoldo","year":"2010","unstructured":"Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, Zanatta M, Valenti MT, Dalle Carbonare L, Lo Cascio V (2010) Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res Off J Am Soc Bone Miner Res 25:447\u2013454","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3992_CR23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","volume":"23","author":"JD Wark","year":"2012","unstructured":"Wark JD, Bensen W, Recknor C, Ryabitseva O, Chiodo J 3rd, Mesenbrink P, de Villiers TJ (2012) Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int :J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA 23:503\u2013512","journal-title":"Osteoporos Int :J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"3992_CR24","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00198-010-1448-2","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E (2011) Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int :J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA 22:2337\u20132345","journal-title":"Osteoporos Int :J Est Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-017-3992-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-3992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-3992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T05:15:33Z","timestamp":1658812533000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-017-3992-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["3992"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-3992-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]}}}